YUSIMRY
PeakmAbadalimumab-aqvh
BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
YUSIMRY (adalimumab-aqvh) is tumor necrosis factor receptor blocking activity [moa]. First approved in 2021.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUSIMRY (adalimumab-aqvh) is a biosimilar to Humira, a TNF-blocking monoclonal antibody administered by injection. It works by binding to and neutralizing tumor necrosis factor (TNF), a key inflammatory cytokine driving multiple autoimmune and inflammatory conditions. This biosimilar targets patients with established TNF-inhibitor indications where cost-effective alternatives to originator Humira are sought.
Peak
Peak lifecycle stage indicates mature commercial operations; teams focus on market penetration, payer relationships, and competitive positioning rather than launch activities.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on YUSIMRY offers exposure to biosimilar commercialization, payer negotiation, and rapid-market dynamics in a peak-lifecycle, competitive setting. Career progression emphasizes market share defense, cost-efficiency strategies, and managed-care navigation rather than novel drug development.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.